Genenta Science
GNTA
5 hedge funds and large institutions have $1.82M invested in Genenta Science in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 2.95% → 2.94% (-0.01%)
13% less capital invested
Capital invested by funds: $2.1M → $1.82M (-$282K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$3.83K |
| 2 |
A
Allianz
Munich,
Germany
|
+$1.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.46K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$361 |
GNTA Hedge Fund Activity: Q2 2025 in Review
5 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Genenta Science (GNTA) for Q2 2025, worth a combined $1.82M — down 13% from $2.1M a quarter earlier.
Fund positioning in GNTA was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was EverSource Wealth Advisors, opening a new position worth an estimated $3.83K. The largest seller was Morgan Stanley, cutting an estimated $5.46K.
- 5 institutional investors held Genenta Science (GNTA) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $1.82M of Genenta Science stock for Q2 2025, down 13% quarter-over-quarter.
- 1 fund opened new Genenta Science positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Genenta Science buyer in Q2 2025 was EverSource Wealth Advisors, an estimated $3.83K added.
- The largest Genenta Science seller in Q2 2025 was Morgan Stanley, an estimated $5.46K sold.
Based on aggregated 13F filings for Q2 2025.